AssetMark’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
AssetMark's ALNY Position: Q3 2026 in Review
AssetMark increased its Alnylam Pharmaceuticals (ALNY) stake by 31% in Q3 2026, buying an estimated $1.13M and bringing the position to 18,767 shares worth $4.63M. The position accounts for 0.01% of the portfolio, ranked #756.
AssetMark first reported a position in ALNY in Q3 2017 and has held it in 24 quarters since. The position peaked at $6.38M in Q4 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- AssetMark held 18,767 shares of Alnylam Pharmaceuticals worth $4.63M as of Q3 2026.
- AssetMark bought 4,437 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $1.13M.
- Alnylam Pharmaceuticals made up 0.01% of AssetMark's portfolio in Q3 2026, its #756 holding.
- AssetMark first reported a position in Alnylam Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
- AssetMark's Alnylam Pharmaceuticals position peaked at $6.38M in Q4 2025.
- 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.